These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31362933)

  • 1. Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure.
    Bayes-Genis A; Núñez J
    Clin Chem; 2019 Oct; 65(10):1187-1189. PubMed ID: 31362933
    [No Abstract]   [Full Text] [Related]  

  • 2. Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
    Bayes-Genis A; Voors AA; Zannad F; Januzzi JL; Mark Richards A; Díez J
    Eur Heart J; 2018 Aug; 39(30):2793-2799. PubMed ID: 28204449
    [No Abstract]   [Full Text] [Related]  

  • 3. Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.
    Ibrahim NE; Gaggin HK; Konstam MA; Januzzi JL
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27582282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neprilysin: Biotarget and Biomarker in Heart Failure.
    Seronde MF; Mebazaa A
    JACC Heart Fail; 2015 Aug; 3(8):645-6. PubMed ID: 26251093
    [No Abstract]   [Full Text] [Related]  

  • 5. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
    Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
    Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Test in Context: Neprilysin: Function, Inhibition, and Biomarker.
    Bayes-Genis A; Barallat J; Richards AM
    J Am Coll Cardiol; 2016 Aug; 68(6):639-653. PubMed ID: 27491909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspective on precision medicine in paediatric heart failure.
    Fridman MD; Mital S
    Clin Sci (Lond); 2017 Mar; 131(6):439-448. PubMed ID: 28265035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac natriuretic peptides in plasma: from prediction to precision medicine.
    Goetze JP; Zois NE
    Lancet Diabetes Endocrinol; 2016 Oct; 4(10):803-5. PubMed ID: 27599813
    [No Abstract]   [Full Text] [Related]  

  • 9. Neprilysin in Heart Failure: From Oblivion to Center Stage.
    Bayés-Genís A
    JACC Heart Fail; 2015 Aug; 3(8):637-40. PubMed ID: 26251091
    [No Abstract]   [Full Text] [Related]  

  • 10. Utilising biomarkers to predict right heart maladaptive phenotype: a step toward precision medicine.
    Pullamsetti SS; Tello K; Seeger W
    Eur Respir J; 2021 Apr; 57(4):. PubMed ID: 33833075
    [No Abstract]   [Full Text] [Related]  

  • 11. Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.
    Wu AC; Kiley JP; Noel PJ; Amur S; Burchard EG; Clancy JP; Galanter J; Inada M; Jones TK; Kropski JA; Loyd JE; Nogee LM; Raby BA; Rogers AJ; Schwartz DA; Sin DD; Spira A; Weiss ST; Young LR; Himes BE
    Am J Respir Crit Care Med; 2018 Dec; 198(12):e116-e136. PubMed ID: 30640517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients?
    Emrich IE; Vodovar N; Feuer L; Untersteller K; Nougue H; Seiler-Mussler S; Fliser D; Launay JM; Heine GH
    Nephrol Dial Transplant; 2019 Jan; 34(1):100-108. PubMed ID: 29635392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging Biomarkers for Precision Medicine in Heart Failure.
    Kennedy SG; Gaggin HK
    J Card Fail; 2023 Apr; 29(4):459-462. PubMed ID: 36907236
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum neprilysin and recurrent hospitalizations after acute heart failure.
    Núñez J; Núñez E; Miñana G; Carratalá A; Sanchis J; Lupón J; Barallat J; Pastor MC; Pascual-Figal D; Bayés-Genís A
    Int J Cardiol; 2016 Oct; 220():742-4. PubMed ID: 27393859
    [No Abstract]   [Full Text] [Related]  

  • 15. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients.
    Bayés-Genís A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2015 Feb; 65(7):657-65. PubMed ID: 25677426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure.
    Vodovar N; Séronde MF; Laribi S; Gayat E; Lassus J; Januzzi JL; Boukef R; Nouira S; Manivet P; Samuel JL; Logeart D; Cohen-Solal A; Richards AM; Launay JM; Mebazaa A;
    JACC Heart Fail; 2015 Aug; 3(8):629-36. PubMed ID: 26251090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure: A Pilot Study.
    Bayés-Genís A; Barallat J; Pascual-Figal D; Nuñez J; Miñana G; Sánchez-Mas J; Galan A; Sanchis J; Zamora E; Pérez-Martínez MT; Lupón J
    JACC Heart Fail; 2015 Aug; 3(8):641-4. PubMed ID: 26251092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    D'Elia E; Iacovoni A; Vaduganathan M; Lorini FL; Perlini S; Senni M
    Eur J Heart Fail; 2017 Jun; 19(6):710-717. PubMed ID: 28326642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision Medicine for Heart Failure: Back to the Future.
    Feldman AM
    J Am Coll Cardiol; 2019 Mar; 73(10):1185-1188. PubMed ID: 30871702
    [No Abstract]   [Full Text] [Related]  

  • 20. Precision medicine in heart failure no longer a visual theory but a realistic opportunity.
    Sinagra G; Porcari A; Merlo M
    Eur J Intern Med; 2020 Jan; 71():20-22. PubMed ID: 31727453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.